<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535001</url>
  </required_header>
  <id_info>
    <org_study_id>N-20110085</org_study_id>
    <nct_id>NCT01535001</nct_id>
  </id_info>
  <brief_title>Structured Non-operative Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Structured Non-operative Treatment of Knee Osteoarthritis - a Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Orthopaedic Division, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Rheumatism Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Association of Danish Physiotherapists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern Orthopaedic Division, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether an algorithm for systematic non-surgical
      treatment consisting of corrective insoles, neuromuscular training, weight loss, patient
      education and pharmacological treatment with paracetamol, non steroidal anti inflammatory
      drugs (NSAIDs) and Pantoprazole provides further improvement in pain, function and quality of
      life than standard non-surgical treatment (information on the disease and how to treat it) in
      patients with knee osteoarthritis.

      The H1-hypothesis is that the treatment algorithm results in a greater increase in quality of
      life and functional capacity and greater reduction in pain than standard treatment at the
      primary endpoint, which is follow-up 12months after the start of the treatment.

      See statistical analysis plan available under &quot;Links&quot; for further description of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Knee osteoarthritis (OA) is the degenerative joint disease that most often requires treatment
      and at the same time the one associated with the greatest social costs. In addition, the
      disease has many personal costs and is greatly contributing to reduced functionality and
      autonomy of older adults.

      It is recommended both nationally and internationally that the treatment of knee
      osteoarthritis should include multiple treatment modalities. Clinical guidelines recommend
      that exercise, weight loss and patient education is the first step in treatment and that
      insoles and pharmacological treatment can be included as a supplement.

      However if the patient is not a candidate for total knee replacement, the patient most often
      receives only information on knee osteoarthritis, and on what they can do to treat the
      disorder and prevent it from being worse. This postponement of treatment can lead to a
      worsening of pain and function and a worse outcome after treatment. Therefore, the current
      treatment strategy for the patient group is problematic.

      The current practice may be due to the lack of studies with high level of evidence that have
      examined the optimal non-operative treatment approach and compared it with the current
      standard treatment for this group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in KOOS4 (Knee Injury and Osteoarthritis Outcome Score)</measure>
    <time_frame>Primary: 12months.</time_frame>
    <description>The average score for four of the five KOOS subscales, covering pain, symptoms, difficulties in functions of daily living, and quality of life (KOOS4), with scores ranging from 0 (worst) to 100 (best).
Between group comparisons of treatment effect (change in KOOS4 from baseline to 1 year follow-up) will be dependent on data distribution. We expect the change to be normally distributed and analysis will be made using a mixed model ANOVA with subject being a random factor and visit (baseline, 3, 6 and 12 months), treatment arm (TKA + MEDIC, MEDIC) and site (Frederikshavn, Farsoe) being fixed factors. Baseline KOOS4 will be a covariate. Furthermore interactions between the fixed factors will be included in the model. P-values and 95% CI will be presented to assess superiority.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D</measure>
    <time_frame>Primary: 12months.</time_frame>
    <description>Between groups comparisons of the change from baseline to the 1 year follow-up in all secondary endpoint will be handled similar to the primary endpoint. See statistical analysis plan for further description (available under &quot;Links&quot;).
Range of EQ-5D Descriptive Index is -0.59 to 1.00 (worst to best), while the EQ VAS goes from 0 to 100 (worst to best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 20-meter Walk</measure>
    <time_frame>Primary: 12months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Five KOOS Subscale Scores From Baseline</measure>
    <time_frame>Primary: 12 months.</time_frame>
    <description>Range of all subscales are 0 to 100 (worst to best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Change in kg From Baseline</measure>
    <time_frame>Primary: 12months.</time_frame>
    <description>Weight change in kg measured without shoes at the same time of day and on the same scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Users of Pain Medication</measure>
    <time_frame>Baseline and 12months.</time_frame>
    <description>With possible answers being yes and no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events Reported at Index Knee</measure>
    <time_frame>Primary: 12months.</time_frame>
    <description>Adverse events (AE) and seriously adverse events (SAE) will be registered in three ways and divided into index knee or sites other than index knee. The project physiotherapist will record any adverse events that the participant experiences or tells them about. For the participants allocated to, or crossing over to, TKA, a project worker will look through hospital records to register if any pre-defined perioperative and postoperative adverse events occurred. At all follow-ups, the assessor will use open-probe questioning to assess adverse events in all participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Time From the Timed Up and Go</measure>
    <time_frame>Primary: 12 months.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Outcomes</measure>
    <time_frame>Baseline, 3months, 6months, 12months and 24months</time_frame>
    <description>Pain intensities on a 100 mm VAS with terminal descriptors of 'no pain' and 'worst pain possible' in various situations.
Number of sites with pain in the previous 24 hours shaded on a region-divided body chart
Pain location and type assessed using the Knee Pain Map.
Maximum isometric muscle strength measured bilaterally in knee flexion and knee extension in a make test using a handheld dynamometer (Powertrack II TM Commander).
Pressure pain thresholds measured bilaterally using a handheld algometer (Algometer Type II) at five sites at the knee and the m. tibialis anterior muscle and the m. extensor carpi radialis longus.
Postural balance assessed using an instrumented force platform (Good Balance), measuring the centre of pressure excursion.
Self-efficacy in improving pain, function and QOL in various situations using a 100 mm VAS with terminal descriptors of 'very unsure' and 'very sure'.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>MEDIC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuromuscular training (NEMEX-TJR)</intervention_name>
    <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.</description>
    <arm_group_label>MEDIC</arm_group_label>
    <other_name>No other</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Information</intervention_name>
    <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
    <arm_group_label>Standard treatment</arm_group_label>
    <other_name>No other</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>1 g x 4/day</description>
    <arm_group_label>MEDIC</arm_group_label>
    <other_name>No other</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Burana</intervention_name>
    <description>400 mg x 3/day for three weeks</description>
    <arm_group_label>MEDIC</arm_group_label>
    <other_name>No other</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>20mg x 1/day for three weeks</description>
    <arm_group_label>MEDIC</arm_group_label>
    <other_name>No other</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary counseling</intervention_name>
    <description>For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.</description>
    <arm_group_label>MEDIC</arm_group_label>
    <other_name>No other</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patient education</intervention_name>
    <description>The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, &quot;Lær at leve med kronisk sygdom (Learn to live with chronic illness)&quot; by The National Board of Health, Denmark and &quot;Artrosskolan Spenshult&quot; in Sweden.</description>
    <arm_group_label>MEDIC</arm_group_label>
    <other_name>No other</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Insoles</intervention_name>
    <description>The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
    <arm_group_label>MEDIC</arm_group_label>
    <other_name>No other</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Knee-OA detected by x-ray (Kellgren &amp; Lawrence grade 1 or greater)

          -  KOOS4 of ≤ 75

          -  Considered not to be a candidate for Total Knee Replacement (TKR) by the orthopedic
             surgeon.

          -  The participant is &gt; 18 years of age.

          -  The participant can provide relevant and adequate, informed consent.

        Exclusion Criteria:

          -  Prior TKA ipsilateral

          -  Rheumatoid arthritis

          -  Mean VAS &gt; 60mm the last week on a 0-100mm scale

          -  Possible pregnancy or planning pregnancy;

          -  Inability to comply with the protocol;

          -  Inadequacy in written and spoken Danish.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren T. Skou, PhD-student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic Research Unit, Aalborg University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewa M. Roos, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Arendt-Nielsen, Dr.Sci.Med.</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Sensory-Motor Interaction (SMI), Department of Health Sciences and Technology, Aalborg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mogens B. Laursen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Orthopaedic Surgery Research Unit, Aalborg University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sten Rasmussen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Orthopaedic Surgery Research Unit, Aalborg University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael S. Rathleff, PhD-student</last_name>
    <role>Study Chair</role>
    <affiliation>Orthopaedic Surgery Research Unit, Aalborg University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ole H. Simonsen, Dr.Sci.Med.</last_name>
    <role>Study Chair</role>
    <affiliation>Orthopaedic Surgery Research Unit, Aalborg University Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Occupational and Physiotherapy, Aalborg Hospital-Aarhus University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farsoe Hospital</name>
      <address>
        <city>Farsø</city>
        <zip>9640</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vendsyssel Hospital, Frederikshavn</name>
      <address>
        <city>Frederikshavn</city>
        <zip>9900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://vbn.aau.dk/da/publications/statistical-analysis-plan-sap-for-medic2(3e75f67a-4333-439a-bb0b-b8e21bc19fb1).html</url>
    <description>Link to the published statistical analysis plan</description>
  </link>
  <reference>
    <citation>Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 Dec;62(12):1145-55. Review.</citation>
    <PMID>14644851</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010 Apr;18(4):476-99. doi: 10.1016/j.joca.2010.01.013. Epub 2010 Feb 11. Review.</citation>
    <PMID>20170770</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008 Feb;16(2):137-62. doi: 10.1016/j.joca.2007.12.013. Review.</citation>
    <PMID>18279766</PMID>
  </reference>
  <reference>
    <citation>Fortin PR, Penrod JR, Clarke AE, St-Pierre Y, Joseph L, Bélisle P, Liang MH, Ferland D, Phillips CB, Mahomed N, Tanzer M, Sledge C, Fossel AH, Katz JN. Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum. 2002 Dec;46(12):3327-30.</citation>
    <PMID>12483739</PMID>
  </reference>
  <reference>
    <citation>Rossi MD, Eberle T, Roche M, Waggoner M, Blake R, Burwell B, Baxter A. Delaying knee replacement and implications on early postoperative outcomes: a pilot study. Orthopedics. 2009 Dec;32(12):885. doi: 10.3928/01477447-20091020-06.</citation>
    <PMID>19968215</PMID>
  </reference>
  <reference>
    <citation>National Board of Health, Denmark. Referenceprogram for knæartrose. Copenhagen: National Board of Health, Denmark; 2007. [22.02.2010] found at: http://www.sst.dk/publ/Publ2007/PLAN/SfR/Refprg_knaeartrose.pdf</citation>
  </reference>
  <reference>
    <citation>Skou ST, Rasmussen S, Laursen MB, Rathleff MS, Arendt-Nielsen L, Simonsen O, Roos EM. The efficacy of 12 weeks non-surgical treatment for patients not eligible for total knee replacement: a randomized controlled trial with 1-year follow-up. Osteoarthritis Cartilage. 2015 Sep;23(9):1465-75. doi: 10.1016/j.joca.2015.04.021. Epub 2015 Apr 30.</citation>
    <PMID>25937024</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <results_first_submitted>December 19, 2015</results_first_submitted>
  <results_first_submitted_qc>December 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2016</results_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis, Knee</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Time Factors</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Combined Modality Therapy</keyword>
  <keyword>Middle Aged</keyword>
  <keyword>Aged</keyword>
  <keyword>Aged, 80 and over</keyword>
  <keyword>Male</keyword>
  <keyword>Female</keyword>
  <keyword>Humans</keyword>
  <keyword>Analysis of Variance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MEDIC</title>
          <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
        </group>
        <group group_id="P2">
          <title>Standard Treatment</title>
          <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MEDIC</title>
          <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet.
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
        </group>
        <group group_id="B2">
          <title>Standard Treatment</title>
          <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="8.7"/>
                    <measurement group_id="B2" value="67.1" spread="9.1"/>
                    <measurement group_id="B3" value="66.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="5.6"/>
                    <measurement group_id="B2" value="29.4" spread="5.2"/>
                    <measurement group_id="B3" value="30.0" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in KOOS4 (Knee Injury and Osteoarthritis Outcome Score)</title>
        <description>The average score for four of the five KOOS subscales, covering pain, symptoms, difficulties in functions of daily living, and quality of life (KOOS4), with scores ranging from 0 (worst) to 100 (best).
Between group comparisons of treatment effect (change in KOOS4 from baseline to 1 year follow-up) will be dependent on data distribution. We expect the change to be normally distributed and analysis will be made using a mixed model ANOVA with subject being a random factor and visit (baseline, 3, 6 and 12 months), treatment arm (TKA + MEDIC, MEDIC) and site (Frederikshavn, Farsoe) being fixed factors. Baseline KOOS4 will be a covariate. Furthermore interactions between the fixed factors will be included in the model. P-values and 95% CI will be presented to assess superiority.</description>
        <time_frame>Primary: 12months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KOOS4 (Knee Injury and Osteoarthritis Outcome Score)</title>
          <description>The average score for four of the five KOOS subscales, covering pain, symptoms, difficulties in functions of daily living, and quality of life (KOOS4), with scores ranging from 0 (worst) to 100 (best).
Between group comparisons of treatment effect (change in KOOS4 from baseline to 1 year follow-up) will be dependent on data distribution. We expect the change to be normally distributed and analysis will be made using a mixed model ANOVA with subject being a random factor and visit (baseline, 3, 6 and 12 months), treatment arm (TKA + MEDIC, MEDIC) and site (Frederikshavn, Farsoe) being fixed factors. Baseline KOOS4 will be a covariate. Furthermore interactions between the fixed factors will be included in the model. P-values and 95% CI will be presented to assess superiority.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="13.0" upper_limit="23.4"/>
                    <measurement group_id="O2" value="7.1" lower_limit="1.4" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D</title>
        <description>Between groups comparisons of the change from baseline to the 1 year follow-up in all secondary endpoint will be handled similar to the primary endpoint. See statistical analysis plan for further description (available under &quot;Links&quot;).
Range of EQ-5D Descriptive Index is -0.59 to 1.00 (worst to best), while the EQ VAS goes from 0 to 100 (worst to best).</description>
        <time_frame>Primary: 12months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D</title>
          <description>Between groups comparisons of the change from baseline to the 1 year follow-up in all secondary endpoint will be handled similar to the primary endpoint. See statistical analysis plan for further description (available under &quot;Links&quot;).
Range of EQ-5D Descriptive Index is -0.59 to 1.00 (worst to best), while the EQ VAS goes from 0 to 100 (worst to best).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Descriptive index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.140" lower_limit="0.095" upper_limit="0.186"/>
                    <measurement group_id="O2" value="0.075" lower_limit="0.018" upper_limit="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EQ VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="-0.4" upper_limit="11.0"/>
                    <measurement group_id="O2" value="7.2" lower_limit="0.1" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 20-meter Walk</title>
        <time_frame>Primary: 12months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 20-meter Walk</title>
          <units>sec</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-1.6" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-1.1" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Five KOOS Subscale Scores From Baseline</title>
        <description>Range of all subscales are 0 to 100 (worst to best).</description>
        <time_frame>Primary: 12 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Five KOOS Subscale Scores From Baseline</title>
          <description>Range of all subscales are 0 to 100 (worst to best).</description>
          <units>units on a scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="12.9" upper_limit="24.6"/>
                    <measurement group_id="O2" value="9.3" lower_limit="2.9" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="10.6" upper_limit="22.0"/>
                    <measurement group_id="O2" value="7.7" lower_limit="1.5" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities of Daily Living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="12.6" upper_limit="24.8"/>
                    <measurement group_id="O2" value="5.9" lower_limit="-0.8" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sports and recreation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="7.8" upper_limit="24.1"/>
                    <measurement group_id="O2" value="12.0" lower_limit="4.8" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="12.9" upper_limit="25.2"/>
                    <measurement group_id="O2" value="5.5" lower_limit="-1.1" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Change in kg From Baseline</title>
        <description>Weight change in kg measured without shoes at the same time of day and on the same scale</description>
        <time_frame>Primary: 12months.</time_frame>
        <population>Only patients with a BMI equal to or &gt;25 were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Change in kg From Baseline</title>
          <description>Weight change in kg measured without shoes at the same time of day and on the same scale</description>
          <population>Only patients with a BMI equal to or &gt;25 were included in this analysis.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-3.8" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-4.1" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Users of Pain Medication</title>
        <description>With possible answers being yes and no</description>
        <time_frame>Baseline and 12months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Users of Pain Medication</title>
          <description>With possible answers being yes and no</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" lower_limit="0.50" upper_limit="0.76"/>
                    <measurement group_id="O2" value="0.56" lower_limit="0.42" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.26" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.42" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Adverse Events Reported at Index Knee</title>
        <description>Adverse events (AE) and seriously adverse events (SAE) will be registered in three ways and divided into index knee or sites other than index knee. The project physiotherapist will record any adverse events that the participant experiences or tells them about. For the participants allocated to, or crossing over to, TKA, a project worker will look through hospital records to register if any pre-defined perioperative and postoperative adverse events occurred. At all follow-ups, the assessor will use open-probe questioning to assess adverse events in all participants.</description>
        <time_frame>Primary: 12months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events Reported at Index Knee</title>
          <description>Adverse events (AE) and seriously adverse events (SAE) will be registered in three ways and divided into index knee or sites other than index knee. The project physiotherapist will record any adverse events that the participant experiences or tells them about. For the participants allocated to, or crossing over to, TKA, a project worker will look through hospital records to register if any pre-defined perioperative and postoperative adverse events occurred. At all follow-ups, the assessor will use open-probe questioning to assess adverse events in all participants.</description>
          <units>Serious adverse events related to knee</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Time From the Timed Up and Go</title>
        <time_frame>Primary: 12 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Time From the Timed Up and Go</title>
          <units>sec</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-1.9" upper_limit="-0.9"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-1.7" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Outcomes</title>
        <description>Pain intensities on a 100 mm VAS with terminal descriptors of 'no pain' and 'worst pain possible' in various situations.
Number of sites with pain in the previous 24 hours shaded on a region-divided body chart
Pain location and type assessed using the Knee Pain Map.
Maximum isometric muscle strength measured bilaterally in knee flexion and knee extension in a make test using a handheld dynamometer (Powertrack II TM Commander).
Pressure pain thresholds measured bilaterally using a handheld algometer (Algometer Type II) at five sites at the knee and the m. tibialis anterior muscle and the m. extensor carpi radialis longus.
Postural balance assessed using an instrumented force platform (Good Balance), measuring the centre of pressure excursion.
Self-efficacy in improving pain, function and QOL in various situations using a 100 mm VAS with terminal descriptors of 'very unsure' and 'very sure'.</description>
        <time_frame>Baseline, 3months, 6months, 12months and 24months</time_frame>
        <population>Since this is exploratory outcomes they will be analyzed in future publications.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDIC</title>
            <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Outcomes</title>
          <description>Pain intensities on a 100 mm VAS with terminal descriptors of 'no pain' and 'worst pain possible' in various situations.
Number of sites with pain in the previous 24 hours shaded on a region-divided body chart
Pain location and type assessed using the Knee Pain Map.
Maximum isometric muscle strength measured bilaterally in knee flexion and knee extension in a make test using a handheld dynamometer (Powertrack II TM Commander).
Pressure pain thresholds measured bilaterally using a handheld algometer (Algometer Type II) at five sites at the knee and the m. tibialis anterior muscle and the m. extensor carpi radialis longus.
Postural balance assessed using an instrumented force platform (Good Balance), measuring the centre of pressure excursion.
Self-efficacy in improving pain, function and QOL in various situations using a 100 mm VAS with terminal descriptors of 'very unsure' and 'very sure'.</description>
          <population>Since this is exploratory outcomes they will be analyzed in future publications.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MEDIC</title>
          <description>60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
Paracetamol: 1 g x 4/day
Burana: 400 mg x 3/day
Pantoprazole: 20mg x 1/day
Dietary counseling: For participants with a BMI equal to or &gt;25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet
Patient education: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA.
Insoles: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes.</description>
        </group>
        <group group_id="E2">
          <title>Standard Treatment</title>
          <description>Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information: Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood transfusion during TKR surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>canalolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Total knee replacement</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Arthrodesis of contralateral foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Knee arthroscopy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pain without loosening of the prosthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fracture of os sacrum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Low back pain radiating to leg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Frature of collum femoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Instability after TKR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Swelling after TKR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>severe physical decline due to influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>heart problems</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>renal-artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Atherosclerosis demanding angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in index knee</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Swelling in index knee</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Decreased range of motion in index knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Calor around index knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Rubor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Achilles Tendinopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Broken toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>foot painof short duration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>intermittent hip pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>sciatic nerve pain of short duration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>ankle sprain (grade I)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pain in the contralateral knee</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>hamstring strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Søren T. Skou</name_or_title>
      <organization>Aalborg University Hospital</organization>
      <phone>+4523708640</phone>
      <email>sots@rn.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

